[go: up one dir, main page]

AR122409A1 - Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas - Google Patents

Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas

Info

Publication number
AR122409A1
AR122409A1 ARP210100824A ARP210100824A AR122409A1 AR 122409 A1 AR122409 A1 AR 122409A1 AR P210100824 A ARP210100824 A AR P210100824A AR P210100824 A ARP210100824 A AR P210100824A AR 122409 A1 AR122409 A1 AR 122409A1
Authority
AR
Argentina
Prior art keywords
concentration
pharmaceutical composition
agent
aav
phenylketonuria
Prior art date
Application number
ARP210100824A
Other languages
English (en)
Inventor
Peter Colosi
Hassibullah Akeefe
Geoffrey Berguig
Rajeev Mahimkar
Haoling Weng
Zhonghua Gu
Marcus Wong
Kidisti Araya
Joyce Chou
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of AR122409A1 publication Critical patent/AR122409A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica que comprende partículas de rAAV a una concentración de al menos 1E13 vg/ml a aproximadamente 1E14 vg/ml que comprende fosfato de sodio a una concentración de aproximadamente 5 a aproximadamente 15 mM, cloruro de sodio a una concentración de aproximadamente 100 mM a aproximadamente 165 mM, un agente crioconservante que es un azúcar, opcionalmente trehalosa, y un poloxámero o polisorbato a una concentración de menos del 0,2% p/v. Reivindicación 13: Una composición farmacéutica que comprende partículas de AAV recombinante (rAAV) a una concentración de al menos 1E13 vg/ml a aproximadamente 1E14 vg/ml, un agente tampón, un agente de isotonicidad, un agente crioconservante y un tensioactivo que es estable durante el almacenamiento a aproximadamente -60ºC (menos sesenta grados centígrados) o menos durante al menos aproximadamente 1 año, 1,5 años o 2 años. Reivindicación 18: Una composición farmacéutica que comprende partículas de rAAV a una concentración de aproximadamente 6E13 vg/ml, fosfato de sodio 10 mM, cloruro de sodio 120 mM, trehalosa dihidrato 74 mM y poloxámero 188 al 0,1% p/v.
ARP210100824A 2020-04-03 2021-03-31 Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas AR122409A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063005049P 2020-04-03 2020-04-03

Publications (1)

Publication Number Publication Date
AR122409A1 true AR122409A1 (es) 2022-09-07

Family

ID=75674959

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100824A AR122409A1 (es) 2020-04-03 2021-03-31 Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas

Country Status (3)

Country Link
AR (1) AR122409A1 (es)
TW (1) TW202144575A (es)
WO (1) WO2021202943A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3491008A2 (en) 2016-07-26 2019-06-05 BioMarin Pharmaceutical Inc. Novel adeno-associated virus capsid proteins
AU2019265560A1 (en) 2018-05-09 2020-11-26 Biomarin Pharmaceutical Inc. Methods of treating phenylketonuria
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
TWI900667B (zh) 2020-10-01 2025-10-11 美商健臻公司 藉由肝導向基因替代療法治療pku之人類pah表現匣
IL302128A (en) 2020-11-02 2023-06-01 Biomarin Pharm Inc A process for the enrichment of adeno-associated virus
EP4493162A1 (en) * 2022-03-14 2025-01-22 Regeneron Pharmaceuticals, Inc. Lyophilized formulations of aav drug products
CN116656740A (zh) * 2023-05-30 2023-08-29 浙江大学 一种腺相关病毒基因治疗载体及其在制备治疗苯丙酮尿症的药物中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US955734A (en) 1909-04-26 1910-04-19 Joseph Wolkerstorfer Display-rack.
ATE78293T1 (de) 1983-05-27 1992-08-15 Texas A & M Univ Sys Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
DK518384A (da) 1984-01-31 1985-07-01 Idaho Res Found Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
ATE497536T1 (de) 2001-10-16 2011-02-15 Nat Inst Of Advanced Ind Scien Neue n-acetylglucosamin transferase, codierende nukleinsäuren, spezifische antikörper, sowie verwendung zur krebsdiagnose
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
HU230406B1 (hu) 2001-11-13 2016-04-28 The Trustees Of The University Of Pennsylvania Eljárás adeno-asszociált vírus(AAV)szekvenciák detektálására és/vagy azonosítására és az azzal azonosított új szekvenciák izolálására
WO2003074714A1 (en) 2002-03-05 2003-09-12 Stichting Voor De Technische Wetenschappen Baculovirus expression system
EP1776364A2 (en) 2003-11-17 2007-04-25 BioMarin Pharmaceutical Inc. Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin
AU2005306686B2 (en) 2004-11-17 2011-06-02 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US8178670B2 (en) 2008-01-07 2012-05-15 Biomarin Pharmaceutical Inc. Method of synthesizing tetrahydrobiopterin
US7943379B2 (en) 2008-04-30 2011-05-17 Nationwide Children's Hospital, Inc. Production of rAAV in vero cells using particular adenovirus helpers
AU2013221212B2 (en) 2012-02-17 2018-08-09 The Children's Hospital Of Philadelphia AAV vector compositions and methods for gene transfer to cells, organs and tissues
EP3491008A2 (en) 2016-07-26 2019-06-05 BioMarin Pharmaceutical Inc. Novel adeno-associated virus capsid proteins
JP7545210B2 (ja) * 2016-11-04 2024-09-04 武田薬品工業株式会社 アデノ随伴ウイルス製剤
WO2018126112A1 (en) 2016-12-30 2018-07-05 The Trustees Of The University Of Pennsylvania Gene therapy for treating phenylketonuria
AU2019265560A1 (en) 2018-05-09 2020-11-26 Biomarin Pharmaceutical Inc. Methods of treating phenylketonuria
AU2019310459A1 (en) * 2018-07-24 2021-02-18 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
CN113993552A (zh) * 2019-04-19 2022-01-28 再生生物股份有限公司 腺相关病毒载体制剂和方法

Also Published As

Publication number Publication date
TW202144575A (zh) 2021-12-01
WO2021202943A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
AR122409A1 (es) Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas
PE20241346A1 (es) Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones que los comprenden
ES2263450T3 (es) Preparaciones de g-csf estabilizadas a largo plazo.
JP7150804B2 (ja) プラミノーゲンを含む医薬組成物及びその使用
ECSP23041058A (es) Formulación subcutánea de anticuerpo anti-her2
ES2391798T3 (es) Composición líquida farmacéutica de toxina botulínica con estabilidad mejorada
ES2345058T3 (es) Formulacion acuosa de hfsh.
AR078161A1 (es) Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
JP2018138578A5 (es)
ME01337B (me) Tečni preparat fsh
RU2009101226A (ru) Составы антагониста vegf, подходящие для интравитреального введения
BR0307898A (pt) Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio
AR040529A1 (es) Formulaciones de hgh en alta concentracion que contienen 1,2-propilenglicol
AR050959A1 (es) Estabilizacion de agentes inmunologicamente activos adyuvados con alumbre
HRP20230929T1 (hr) Stabilni pripravci semaglutida i njihova upotreba
ES2375706T3 (es) Composiciones de alfa 1-antitripsina y métodos de tratamiento que usan tales composiciones.
AR126417A1 (es) Composición farmacéutica de virus no encapsulado
BR112023019201A2 (pt) Composição farmacêutica aquosa ou composição farmacêutica liofilizada
Prankerd et al. Pulmonary delivery of an ultra-fine oxytocin dry powder formulation: potential for treatment of postpartum haemorrhage in developing countries
AR127533A1 (es) INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS
PE20200847A1 (es) Composiciones que contienen dulaglutida
CL2024001520A1 (es) Nueva composición farmacéutica oral y régimen de dosificación para la terapia de enfermedades pulmonares intersticiales
KR101699677B1 (ko) 고나도트로핀을 위한 제제
AR127217A1 (es) Tratamiento de angioedema hereditario con vectores de genoterapia de aav y formulaciones terapéuticas
HRP20220896T1 (hr) Liofilizirana farmaceutska formulacija i njena upotreba

Legal Events

Date Code Title Description
FB Suspension of granting procedure